Geomechanical Modeling

The subject of geomechanical modeling encompasses a wide range of important elements. Post-transplant lymphoproliferative disorder - Radiopaedia.org. PTLD may be focal or diffuse and can affect almost any organ system and even the allograft. It usually manifests as extranodal disease, and can occur in a variety of locations, including 8,9: 18F-FDG PET/CT imaging of posttransplant lymphoproliferative disorder ....

Imaging of Posttransplantation Lymphoproliferative Disorder after Solid .... Radiological Imaging in the Evaluation of Lymphoproliferative Disorders .... Computed tomography (CT) imaging is one of the most widely used modalities for detecting and staging LPDs in post-transplant patients due to its accessibility, rapid acquisition, and ability to visualize anatomical structures in detail.

Understanding Post-Transplant Lymphoproliferative Disorder (PTLD). PTLD is a form of lymphoma, a cancer of the lymphatic system where white blood cells change into cancer cells that can grow out of control and spread throughout the body. If it occurs, PTLD is most common in the first year after transplant, although it can form later.

In this context, how Useful is PET/CT Imaging in the Management of Post-Transplant .... Here, we report our first experience with the use of PET/CT (positron emission tomography combined with computed tomogram) for the management of patients with PTLD after liver transplantation. To investigate the chest computed tomography (CT) and F-18 fluoro-2-deoxy-d-glucose positron emission tomographic (FDG-PET) findings of posttransplant lymphoproliferative disorder (PTLD) in the thorax. 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative ....

Advanced imaging modalities such as 18F-FDG PET/CT have played an increasingly important role and have shown high sensitivity and specificity in detection, staging, and assessing treatment response in multiple clinical studies over the last two decades. PTLD is a major cause of mortality and morbidity, with mortality rates of up to 40%–70% reported in patients with solid organ transplants (1). Symptoms range from fever, malaise, and flu-like illness to ful-minant systemic disease.